European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research

Objective:To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis. In particular, the results of a web-based Delphi exercise aimed at sele...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the Rheumatic Diseases Vol. 68; no. 5; pp. 629 - 634
Main Authors Avouac, J, Kowal-Bielecka, O, Landewe, R, Chwiesko, S, Miniati, I, Czirjak, L, Clements, P, Denton, C, Farge, D, Fligelstone, K, Földvari, I, Furst, D E, Müller-Ladner, U, Seibold, J, Silver, R M, Takehara, K, Toth, B Garay, Tyndall, A, Valentini, G, van den Hoogen, F, Wigley, F, Zulian, F, Matucci-Cerinic, M
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and European League Against Rheumatism 01.05.2009
Elsevier BV
BMJ Publishing Group
Elsevier Limited
Subjects
Online AccessGet full text
ISSN0003-4967
1468-2060
1468-2060
DOI10.1136/ard.2008.095299

Cover

Abstract Objective:To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis. In particular, the results of a web-based Delphi exercise aimed at selection of research questions and evidence from systematic literature research, as parts of the development of these recommendations, are presented in detail.Methods:In agreement with the EULAR standard operating procedures a Task Force was created that consisted of the EUSTAR board members, 10 systemic sclerosis (SSc) experts invited from outside the EUSTAR board and representing Europe, the USA and Japan, a clinical epidemiologist, 2 patients with SSc and 3 fellows for literature research. All EUSTAR centres were invited to contribute to the development of recommendations through submission and preliminary selection of the research questions. The systematic literature research was performed using the Pubmed, Medline, EMBASE and Cochrane databases. Retrieved trials were evaluated according to the Jadad classification, and the level of evidence was graded from 1 to 4. Outcome data for efficacy and adverse events were abstracted and effect size, number needed to treat (NNT) and number needed to harm (NNH) were calculated when appropriate.Results:In all, 65 EUSTAR Centres provided 304 research questions concerning SSc treatment. These questions were aggregated, subdivided into 19 treatment categories and then subjected to preliminary selection by a web-based Delphi technique. The final set of 26 research questions was created by the Expert Committee based on the results of the Delphi exercise and the expert’s experience.Conclusions:This paper is a comprehensive summary of the methods we used to build recommendations for the drug treatment of systemic sclerosis, combining an evidence based approach and expert opinion.
AbstractList To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis. In particular, the results of a web-based Delphi exercise aimed at selection of research questions and evidence from systematic literature research, as parts of the development of these recommendations, are presented in detail. In agreement with the EULAR standard operating procedures a Task Force was created that consisted of the EUSTAR board members, 10 systemic sclerosis (SSc) experts invited from outside the EUSTAR board and representing Europe, the USA and Japan, a clinical epidemiologist, 2 patients with SSc and 3 fellows for literature research. All EUSTAR centres were invited to contribute to the development of recommendations through submission and preliminary selection of the research questions. The systematic literature research was performed using the Pubmed, Medline, EMBASE and Cochrane databases. Retrieved trials were evaluated according to the Jadad classification, and the level of evidence was graded from 1 to 4. Outcome data for efficacy and adverse events were abstracted and effect size, number needed to treat (NNT) and number needed to harm (NNH) were calculated when appropriate. In all, 65 EUSTAR Centres provided 304 research questions concerning SSc treatment. These questions were aggregated, subdivided into 19 treatment categories and then subjected to preliminary selection by a web-based Delphi technique. The final set of 26 research questions was created by the Expert Committee based on the results of the Delphi exercise and the expert's experience. This paper is a comprehensive summary of the methods we used to build recommendations for the drug treatment of systemic sclerosis, combining an evidence based approach and expert opinion.
To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis. In particular, the results of a web-based Delphi exercise aimed at selection of research questions and evidence from systematic literature research, as parts of the development of these recommendations, are presented in detail.OBJECTIVETo describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis. In particular, the results of a web-based Delphi exercise aimed at selection of research questions and evidence from systematic literature research, as parts of the development of these recommendations, are presented in detail.In agreement with the EULAR standard operating procedures a Task Force was created that consisted of the EUSTAR board members, 10 systemic sclerosis (SSc) experts invited from outside the EUSTAR board and representing Europe, the USA and Japan, a clinical epidemiologist, 2 patients with SSc and 3 fellows for literature research. All EUSTAR centres were invited to contribute to the development of recommendations through submission and preliminary selection of the research questions. The systematic literature research was performed using the Pubmed, Medline, EMBASE and Cochrane databases. Retrieved trials were evaluated according to the Jadad classification, and the level of evidence was graded from 1 to 4. Outcome data for efficacy and adverse events were abstracted and effect size, number needed to treat (NNT) and number needed to harm (NNH) were calculated when appropriate.METHODSIn agreement with the EULAR standard operating procedures a Task Force was created that consisted of the EUSTAR board members, 10 systemic sclerosis (SSc) experts invited from outside the EUSTAR board and representing Europe, the USA and Japan, a clinical epidemiologist, 2 patients with SSc and 3 fellows for literature research. All EUSTAR centres were invited to contribute to the development of recommendations through submission and preliminary selection of the research questions. The systematic literature research was performed using the Pubmed, Medline, EMBASE and Cochrane databases. Retrieved trials were evaluated according to the Jadad classification, and the level of evidence was graded from 1 to 4. Outcome data for efficacy and adverse events were abstracted and effect size, number needed to treat (NNT) and number needed to harm (NNH) were calculated when appropriate.In all, 65 EUSTAR Centres provided 304 research questions concerning SSc treatment. These questions were aggregated, subdivided into 19 treatment categories and then subjected to preliminary selection by a web-based Delphi technique. The final set of 26 research questions was created by the Expert Committee based on the results of the Delphi exercise and the expert's experience.RESULTSIn all, 65 EUSTAR Centres provided 304 research questions concerning SSc treatment. These questions were aggregated, subdivided into 19 treatment categories and then subjected to preliminary selection by a web-based Delphi technique. The final set of 26 research questions was created by the Expert Committee based on the results of the Delphi exercise and the expert's experience.This paper is a comprehensive summary of the methods we used to build recommendations for the drug treatment of systemic sclerosis, combining an evidence based approach and expert opinion.CONCLUSIONSThis paper is a comprehensive summary of the methods we used to build recommendations for the drug treatment of systemic sclerosis, combining an evidence based approach and expert opinion.
Objective: To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis. In particular, the results of a web-based Delphi exercise aimed at selection of research questions and evidence from systematic literature research, as parts of the development of these recommendations, are presented in detail. Methods: In agreement with the EULAR standard operating procedures a Task Force was created that consisted of the EUSTAR board members, 10 systemic sclerosis (SSc) experts invited from outside the EUSTAR board and representing Europe, the USA and Japan, a clinical epidemiologist, 2 patients with SSc and 3 fellows for literature research. All EUSTAR centres were invited to contribute to the development of recommendations through submission and preliminary selection of the research questions. The systematic literature research was performed using the Pubmed, Medline, EMBASE and Cochrane databases. Retrieved trials were evaluated according to the Jadad classification, and the level of evidence was graded from 1 to 4. Outcome data for efficacy and adverse events were abstracted and effect size, number needed to treat (NNT) and number needed to harm (NNH) were calculated when appropriate. Results: In all, 65 EUSTAR Centres provided 304 research questions concerning SSc treatment. These questions were aggregated, subdivided into 19 treatment categories and then subjected to preliminary selection by a web-based Delphi technique. The final set of 26 research questions was created by the Expert Committee based on the results of the Delphi exercise and the expert's experience. Conclusions: This paper is a comprehensive summary of the methods we used to build recommendations for the drug treatment of systemic sclerosis, combining an evidence based approach and expert opinion.
Author Zulian, F
Czirjak, L
Miniati, I
Földvari, I
Valentini, G
Farge, D
Tyndall, A
Furst, D E
Seibold, J
Müller-Ladner, U
Avouac, J
Chwiesko, S
Matucci-Cerinic, M
Silver, R M
Wigley, F
Landewe, R
Fligelstone, K
Takehara, K
Clements, P
Denton, C
Toth, B Garay
van den Hoogen, F
Kowal-Bielecka, O
Author_xml – sequence: 1
  givenname: J
  surname: Avouac
  fullname: Avouac, J
  email: cerinic@unifi.it
  organization: Rheumatology A Department, RDU, Paris, France
– sequence: 2
  givenname: O
  surname: Kowal-Bielecka
  fullname: Kowal-Bielecka, O
  email: cerinic@unifi.it
  organization: Rheumatology Department, Medical University, Bialystok, Poland
– sequence: 3
  givenname: R
  surname: Landewe
  fullname: Landewe, R
  email: cerinic@unifi.it
  organization: Rheumatology Department, University Hospital, Maastricht, Netherlands
– sequence: 4
  givenname: S
  surname: Chwiesko
  fullname: Chwiesko, S
  email: cerinic@unifi.it
  organization: Rheumatology Department, Medical University, Bialystok, Poland
– sequence: 5
  givenname: I
  surname: Miniati
  fullname: Miniati, I
  email: cerinic@unifi.it
  organization: Rheumatology Department, UF, Florence, Italy
– sequence: 6
  givenname: L
  surname: Czirjak
  fullname: Czirjak, L
  email: cerinic@unifi.it
  organization: Rheumatology Department, University of Pecs, Pecs, Hungary
– sequence: 7
  givenname: P
  surname: Clements
  fullname: Clements, P
  email: cerinic@unifi.it
  organization: Rheumatology Department, University of California Los Angeles, Los Angeles, California, USA
– sequence: 8
  givenname: C
  surname: Denton
  fullname: Denton, C
  email: cerinic@unifi.it
  organization: Rheumatology Department, Royal Free Hospital, London, UK
– sequence: 9
  givenname: D
  surname: Farge
  fullname: Farge, D
  email: cerinic@unifi.it
  organization: Internal Medicine Department, Hopital St Louis, Paris, France
– sequence: 10
  givenname: K
  surname: Fligelstone
  fullname: Fligelstone, K
  email: cerinic@unifi.it
  organization: Scleroderma Association, Federation European Scleroderma Associations (FESCA), Harlesden, UK
– sequence: 11
  givenname: I
  surname: Földvari
  fullname: Földvari, I
  email: cerinic@unifi.it
  organization: Rheumatology Department, Klinik Eilbek, Hamburg, Germany
– sequence: 12
  givenname: D E
  surname: Furst
  fullname: Furst, D E
  email: cerinic@unifi.it
  organization: Rheumatology Department, University of California Los Angeles, Los Angeles, California, USA
– sequence: 13
  givenname: U
  surname: Müller-Ladner
  fullname: Müller-Ladner, U
  email: cerinic@unifi.it
  organization: Rheumatology Department, University of Giessen, Bad Nauheim, Germany
– sequence: 14
  givenname: J
  surname: Seibold
  fullname: Seibold, J
  email: cerinic@unifi.it
  organization: Rheumatology Department, University of Michigan, Ann Arbor, Michigan, USA
– sequence: 15
  givenname: R M
  surname: Silver
  fullname: Silver, R M
  email: cerinic@unifi.it
  organization: Rheumatology Department, Medical University of South Carolina, Charleston, Virginia, USA
– sequence: 16
  givenname: K
  surname: Takehara
  fullname: Takehara, K
  email: cerinic@unifi.it
  organization: Dermatology Department, University School of Medicine, Kanazawa, Japan
– sequence: 17
  givenname: B Garay
  surname: Toth
  fullname: Toth, B Garay
  email: cerinic@unifi.it
  organization: Federation European Scleroderma Associations (FESCA), Budapest, Hungary
– sequence: 18
  givenname: A
  surname: Tyndall
  fullname: Tyndall, A
  email: cerinic@unifi.it
  organization: Rheumatology Department, University Hospital, Basel, Switzerland
– sequence: 19
  givenname: G
  surname: Valentini
  fullname: Valentini, G
  email: cerinic@unifi.it
  organization: Rheumatology Department, Second University, Naples, Italy
– sequence: 20
  givenname: F
  surname: van den Hoogen
  fullname: van den Hoogen, F
  email: cerinic@unifi.it
  organization: Rheumatology Department, Radboud University Medical Center, Nijmegen, Netherlands
– sequence: 21
  givenname: F
  surname: Wigley
  fullname: Wigley, F
  email: cerinic@unifi.it
  organization: Rheumatology Department, John Hopkins University, Baltimore, Maryland, USA
– sequence: 22
  givenname: F
  surname: Zulian
  fullname: Zulian, F
  email: cerinic@unifi.it
  organization: Rheumatology Department, University of Padua, Padua, Italy
– sequence: 23
  givenname: M
  surname: Matucci-Cerinic
  fullname: Matucci-Cerinic, M
  email: cerinic@unifi.it
  organization: Rheumatology Department, UF, Florence, Italy
BackLink https://cir.nii.ac.jp/crid/1871428067716692992$$DView record in CiNii
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21330261$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/18957486$$D View this record in MEDLINE/PubMed
BookMark eNqFkk2P0zAQhiO0iP2AMzdkiQ8BUru2E9sJt6oUFqmAaLu9Ro4zad1N4mI7EvtH-T04TdmV9gAXW_Y87zujmTmPTlrTQhQ9J3hMSMwvpS3HFON0jDNGs-xRdEYSno4o5vgkOsMYx6Mk4-I0OnduF544JemT6JSkGRNJys-i37POmj3IFs1BbjpAk43UrfNosYWukV67Br2dXc8ni3doqWqwpgTbSLSyWtZItiVagANp1RZtrOn2Pbxc9bQFZZoG2jKYmNahyljkt4C8BenDv0emQu7WeWi0Qu7g7bT7gBrwW1O6Pgy1LIw9GBxyWXBd7d29MoQUqrWHAHUWeuBQzNPocSVrB8-O90V0_Wm2ml6N5t8_f5lO5qOCJdyPCE2SlAgss5JRKkBVIsuKgsVcsbRKYipimhAQOAXBmCIFxwyUEHHJJMuYjC-iN4Pv3pqfHTifN9opqGvZgulczgWhmcAkgC8fgDvT2TbUlhMhRMqEyFigXhyprmigzPdWN9Le5n_nFYDXR0A6JevKylZpd8dREseY8j7d5cCp0FRnobq3wnm_OXnYnLzfnHzYnKBgDxRK-0PnvZW6_ofu1aBrtQ6S_iSpIAlNMReCcJ4FigZsNGA6jO3XXTXS3oQexYLl39bTnH9dfrxar3_kq8C_H_ii2f239j_Gvu__
CODEN ARDIAO
CitedBy_id crossref_primary_10_1002_acr_25467
crossref_primary_10_1016_j_semarthrit_2012_01_003
crossref_primary_10_2217_imt_10_34
crossref_primary_10_1590_S0100_39842009000300005
crossref_primary_10_3899_jrheum_090668
crossref_primary_10_1007_s11136_011_9982_8
crossref_primary_10_1007_s12016_017_8636_1
crossref_primary_10_1007_s00393_010_0649_6
crossref_primary_10_1186_s13023_021_01944_9
crossref_primary_10_1155_2011_976427
crossref_primary_10_1177_2397198317750043
crossref_primary_10_1007_s10067_011_1734_1
crossref_primary_10_1007_s00393_009_0523_6
crossref_primary_10_1155_2010_363679
crossref_primary_10_1080_0886022X_2025_2463583
crossref_primary_10_3390_reports7030066
crossref_primary_10_1038_nrrheum_2012_191
crossref_primary_10_1586_17474124_2016_1095088
crossref_primary_10_3390_medicina59020247
crossref_primary_10_1186_s13023_021_01733_4
crossref_primary_10_1136_annrheumdis_2016_209909
crossref_primary_10_1016_j_rhum_2009_11_006
crossref_primary_10_3390_ijms20184337
crossref_primary_10_1136_rmdopen_2015_000159
crossref_primary_10_1136_ard_2008_096677
crossref_primary_10_1002_art_30423
crossref_primary_10_1016_j_jht_2023_09_013
crossref_primary_10_1093_ehjci_jes047
crossref_primary_10_1111_j_1600_0625_2010_01082_x
crossref_primary_10_1016_j_autrev_2017_07_018
crossref_primary_10_1136_annrheumdis_2013_203997
crossref_primary_10_1016_j_explore_2013_10_001
crossref_primary_10_1016_j_jbspin_2009_05_015
crossref_primary_10_1093_rheumatology_keq355
crossref_primary_10_3390_ijms26062421
Cites_doi 10.1136/ard.2006.054346
10.1136/ard.2005.036038
10.1136/ard.2007.078923
10.1002/art.1780230510
10.1111/j.1572-0241.2005.50120.x
10.1136/bmj.318.7183.593
10.1136/ard.2004.023697
10.1136/ard.2006.062901
10.1016/0197-2456(95)00134-4
10.1136/bmj.311.7001.376
10.1136/bmj.310.6977.452
10.1002/sim.4780101105
10.1093/rheumatology/keh253
10.1056/NEJM198806303182605
ContentType Journal Article
Copyright 2009 BMJ Publishing Group and European League Against Rheumatism
2009 INIST-CNRS
Copyright: 2009 2009 BMJ Publishing Group and European League Against Rheumatism
Copyright_xml – notice: 2009 BMJ Publishing Group and European League Against Rheumatism
– notice: 2009 INIST-CNRS
– notice: Copyright: 2009 2009 BMJ Publishing Group and European League Against Rheumatism
CorporateAuthor EUSTAR Coauthors
CorporateAuthor_xml – name: EUSTAR Coauthors
DBID BSCLL
RYH
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
88I
8AF
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
BTHHO
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9-
K9.
LK8
M0R
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
DOI 10.1136/ard.2008.095299
DatabaseName Istex
CiNii Complete
CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
STEM Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
Proquest Central
Natural Science Collection
BMJ Journals
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Consumer Health Database
Health & Medical Collection (Alumni)
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
ProQuest Central Student


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-2060
EndPage 634
ExternalDocumentID 4008487471
18957486
21330261
10_1136_ard_2008_095299
ark_67375_NVC_6MSDHVVQ_T
annrheumdis
Genre Journal Article
GroupedDBID ---
.55
.GJ
.VT
169
23M
2WC
39C
3O-
4.4
40O
53G
5GY
5RE
5VS
6J9
7X7
7~S
88E
88I
8AF
8FE
8FH
8FI
8FJ
8R4
8R5
AAHLL
AAKAS
AAOJX
AAWJN
AAWTL
AAXUO
ABAAH
ABJNI
ABKDF
ABMQD
ABOCM
ABTFR
ABUWG
ABVAJ
ACGFO
ACGFS
ACGOD
ACGTL
ACHTP
ACMFJ
ACOAB
ACOFX
ACPRK
ACQSR
ACTZY
ADBBV
ADCEG
ADFRT
ADUGQ
ADZCM
AEKJL
AENEX
AFKRA
AFWFF
AGQPQ
AHMBA
AHNKE
AHQMW
AJYBZ
AKKEP
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BKNYI
BLJBA
BOMFT
BPHCQ
BTFSW
BTHHO
BVXVI
C1A
C45
CAG
CCPQU
COF
CS3
CXRWF
DIK
DWQXO
E3Z
EBS
EJD
F5P
FDB
FYUFA
GNUQQ
H13
HAJ
HCIFZ
HMCUK
HYE
HZ~
IAO
IEA
IHR
INH
INR
IOF
ITC
J5H
K9-
KQ8
L7B
LK8
M0R
M1P
M2P
M7P
N9A
NTWIH
NXWIF
O9-
OK1
OVD
P2P
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R53
RHI
RMJ
RPM
RV8
RWL
RXW
TAE
TEORI
TR2
UAW
UKHRP
UYXKK
V24
VM9
VVN
W2D
W8F
WH7
WOQ
X6Y
X7M
YFH
YOC
YQY
ZGI
ZXP
0R~
3V.
BSCLL
FRP
IGG
RHF
AALRI
PHGZM
RYH
AAFWJ
AAYXX
CITATION
IQODW
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
PKN
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
ID FETCH-LOGICAL-b546t-12448170a9d5227ecf799bb536c58f43273241e708e755c1b605ec773d5a595a3
IEDL.DBID BENPR
ISSN 0003-4967
1468-2060
IngestDate Fri Sep 05 07:58:40 EDT 2025
Fri Jul 25 11:07:24 EDT 2025
Sat Feb 15 01:21:13 EST 2025
Mon Jul 21 09:16:53 EDT 2025
Tue Jul 01 00:53:32 EDT 2025
Thu Apr 24 23:11:22 EDT 2025
Thu Jun 26 22:53:46 EDT 2025
Wed Oct 30 09:24:00 EDT 2024
Thu Apr 24 23:09:04 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Elaboration
Immunopathology
Connective tissue disease
Skin disease
Treatment
Systemic disease
Diseases of the osteoarticular system
Rheumatology
Autoimmune disease
Rheumatism
Scleroderma
Recommendation
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b546t-12448170a9d5227ecf799bb536c58f43273241e708e755c1b605ec773d5a595a3
Notes ArticleID:ar95299
ark:/67375/NVC-6MSDHVVQ-T
PMID:18957486
istex:F806B63AD2F15DB13F5F649FB9004F6769B5FD18
href:annrheumdis-68-629.pdf
local:annrheumdis;68/5/629
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-0613-1306
0000-0002-2463-218x
0000-0002-2479-3485
0000-0002-7852-9137
PMID 18957486
PQID 1777857795
PQPubID 2041045
PageCount 6
ParticipantIDs proquest_miscellaneous_67129701
proquest_journals_1777857795
pubmed_primary_18957486
pascalfrancis_primary_21330261
crossref_primary_10_1136_ard_2008_095299
crossref_citationtrail_10_1136_ard_2008_095299
nii_cinii_1871428067716692992
istex_primary_ark_67375_NVC_6MSDHVVQ_T
bmj_primary_10_1136_ard_2008_095299
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-05-01
PublicationDateYYYYMMDD 2009-05-01
PublicationDate_xml – month: 05
  year: 2009
  text: 2009-05-01
  day: 01
PublicationDecade 2000
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
– name: Kidlington
PublicationTitle Annals of the Rheumatic Diseases
PublicationTitleAlternate Ann Rheum Dis
PublicationYear 2009
Publisher BMJ Publishing Group Ltd and European League Against Rheumatism
Elsevier BV
BMJ Publishing Group
Elsevier Limited
Publisher_xml – name: BMJ Publishing Group Ltd and European League Against Rheumatism
– name: Elsevier BV
– name: BMJ Publishing Group
– name: Elsevier Limited
References Allanore, Borderie, Airo, Guiducci, Czirjak, Nasonov 2007; 66
Jones, Hunter 1995; 311
Walker, Tyndall, Czirjak, Denton, Farge-Bancel, Kowal-Bielecka 2007; 66
Jadad, Moore, Carroll, Jenkinson, Reynolds, Gavaghan 1996; 17
Whitehead, Whitehead 1991; 10
Cook, Sackett 1995; 310
Le Guern, Mahr, Mouthon, Jeanneret, Carzon, Guillevin 2004; 43
1980; 23
Sierra 2005; 100
Laupacis, Sackett, Roberts 1988; 318
Wallberg-Jonsson, Ohman, Dahlqvist 1997; 24
Khanna, Lovell, Giannini, Clements, Merkel, Seibold 2008; 67
Tyndall, Mueller-Ladner, Matucci-Cerinic 2005; 64
Lipsey, Wilson 2000; 49
Dougados, Betteridge, Burmester, Euller-Ziegler, Guillemin, Hirvonen 2004; 63
LeRoy, Black, Fleischmajer, Jablonska, Krieg, Medsger 1988; 15
Furst, Khanna, Matucci-Cerinic, Clements, Steen, Pope 2007; 34
Shekelle, Woolf, Eccles, Grimshaw 1999; 318
Shekelle (10.1136/ard.2008.095299_bib12) 1999; 318
Khanna (10.1136/ard.2008.095299_bib10) 2008; 67
Lipsey (10.1136/ard.2008.095299_bib13) 2000; 49
Wallberg-Jonsson (10.1136/ard.2008.095299_bib19) 1997; 24
LeRoy (10.1136/ard.2008.095299_bib8) 1988; 15
Dougados (10.1136/ard.2008.095299_bib5) 2004; 63
Tyndall (10.1136/ard.2008.095299_bib3) 2005; 64
Allanore (10.1136/ard.2008.095299_bib2) 2007; 66
Le Guern (10.1136/ard.2008.095299_bib1) 2004; 43
Furst (10.1136/ard.2008.095299_bib9) 2007; 34
(10.1136/ard.2008.095299_bib7) 1980; 23
Cohen (10.1136/ard.2008.095299_bib14) 1988
Laupacis (10.1136/ard.2008.095299_bib17) 1988; 318
Walker (10.1136/ard.2008.095299_bib4) 2007; 66
Jadad (10.1136/ard.2008.095299_bib11) 1996; 17
Whitehead (10.1136/ard.2008.095299_bib16) 1991; 10
Cook (10.1136/ard.2008.095299_bib15) 1995; 310
Sierra (10.1136/ard.2008.095299_bib18) 2005; 100
Jones (10.1136/ard.2008.095299_bib6) 1995; 311
References_xml – volume: 17
  start-page: 1
  year: 1996
  article-title: Assessing the quality of reports of randomized clinical trials: is blinding necessary?
  publication-title: Control Clin Trials
– volume: 43
  start-page: 1129
  year: 2004
  article-title: Prevalence of systemic sclerosis in a French multi-ethnic county.
  publication-title: Rheumatology (Oxford)
– volume: 63
  start-page: 1172
  year: 2004
  article-title: EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees.
  publication-title: Ann Rheum Dis
– volume: 311
  start-page: 376
  year: 1995
  article-title: Consensus methods for medical and health services research.
  publication-title: BMJ
– volume: 15
  start-page: 202
  year: 1988
  article-title: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.
  publication-title: J Rheumatol
– volume: 318
  start-page: 593
  year: 1999
  article-title: Clinical guidelines: developing guidelines.
  publication-title: BMJ
– volume: 23
  start-page: 581
  year: 1980
  article-title: Preliminary criteria for the classification of systemic sclerosis (scleroderma).
  publication-title: Arthritis Rheum
– volume: 66
  start-page: 257
  year: 2007
  article-title: Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients.
  publication-title: Ann Rheum Dis
– volume: 67
  start-page: 703
  year: 2008
  article-title: Development of a provisional core set of response measures for clinical trials of systemic sclerosis.
  publication-title: Ann Rheum Dis
– volume: 10
  start-page: 1665
  year: 1991
  article-title: A general parametric approach to the meta-analysis of randomized clinical trials.
  publication-title: Stat Med
– volume: 49
  start-page: 13
  year: 2000
  article-title: Practical meta-analysis.
  publication-title: SAGE
– volume: 64
  start-page: 1107
  year: 2005
  article-title: Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database.
  publication-title: Ann Rheum Dis
– volume: 66
  start-page: 754
  year: 2007
  article-title: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
  publication-title: Ann Rheum Dis
– volume: 100
  start-page: 1661
  year: 2005
  article-title: Evidence-Based Medicine (EBM) in practice: applying number needed to treat and number needed to harm.
  publication-title: Am J Gastroenterol
– volume: 34
  start-page: 1194
  year: 2007
  article-title: Systemic sclerosis – continuing progress in developing clinical measures of response.
  publication-title: J Rheumatol
– volume: 310
  start-page: 452
  year: 1995
  article-title: The number needed to treat: a clinically useful measure of treatment effect.
  publication-title: BMJ
– volume: 318
  start-page: 1728
  year: 1988
  article-title: An assessment of clinically useful measures of the consequences of treatment.
  publication-title: N Engl J Med
– volume: 24
  start-page: 445
  year: 1997
  article-title: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.
  publication-title: J Rheumatol
– volume: 66
  start-page: 257
  year: 2007
  ident: 10.1136/ard.2008.095299_bib2
  article-title: Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients.
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2006.054346
– volume: 15
  start-page: 202
  year: 1988
  ident: 10.1136/ard.2008.095299_bib8
  article-title: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.
  publication-title: J Rheumatol
– volume: 64
  start-page: 1107
  year: 2005
  ident: 10.1136/ard.2008.095299_bib3
  article-title: Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group database.
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2005.036038
– volume: 67
  start-page: 703
  year: 2008
  ident: 10.1136/ard.2008.095299_bib10
  article-title: Development of a provisional core set of response measures for clinical trials of systemic sclerosis.
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2007.078923
– volume: 49
  start-page: 13
  year: 2000
  ident: 10.1136/ard.2008.095299_bib13
  article-title: Practical meta-analysis.
  publication-title: SAGE
– volume: 23
  start-page: 581
  year: 1980
  ident: 10.1136/ard.2008.095299_bib7
  article-title: Preliminary criteria for the classification of systemic sclerosis (scleroderma).
  publication-title: Arthritis Rheum
  doi: 10.1002/art.1780230510
– volume: 100
  start-page: 1661
  year: 2005
  ident: 10.1136/ard.2008.095299_bib18
  article-title: Evidence-Based Medicine (EBM) in practice: applying number needed to treat and number needed to harm.
  publication-title: Am J Gastroenterol
  doi: 10.1111/j.1572-0241.2005.50120.x
– volume: 318
  start-page: 593
  year: 1999
  ident: 10.1136/ard.2008.095299_bib12
  article-title: Clinical guidelines: developing guidelines.
  publication-title: BMJ
  doi: 10.1136/bmj.318.7183.593
– year: 1988
  ident: 10.1136/ard.2008.095299_bib14
– volume: 63
  start-page: 1172
  year: 2004
  ident: 10.1136/ard.2008.095299_bib5
  article-title: EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees.
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2004.023697
– volume: 24
  start-page: 445
  year: 1997
  ident: 10.1136/ard.2008.095299_bib19
  article-title: Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.
  publication-title: J Rheumatol
– volume: 66
  start-page: 754
  year: 2007
  ident: 10.1136/ard.2008.095299_bib4
  article-title: Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2006.062901
– volume: 34
  start-page: 1194
  year: 2007
  ident: 10.1136/ard.2008.095299_bib9
  article-title: Systemic sclerosis – continuing progress in developing clinical measures of response.
  publication-title: J Rheumatol
– volume: 17
  start-page: 1
  year: 1996
  ident: 10.1136/ard.2008.095299_bib11
  article-title: Assessing the quality of reports of randomized clinical trials: is blinding necessary?
  publication-title: Control Clin Trials
  doi: 10.1016/0197-2456(95)00134-4
– volume: 311
  start-page: 376
  year: 1995
  ident: 10.1136/ard.2008.095299_bib6
  article-title: Consensus methods for medical and health services research.
  publication-title: BMJ
  doi: 10.1136/bmj.311.7001.376
– volume: 310
  start-page: 452
  year: 1995
  ident: 10.1136/ard.2008.095299_bib15
  article-title: The number needed to treat: a clinically useful measure of treatment effect.
  publication-title: BMJ
  doi: 10.1136/bmj.310.6977.452
– volume: 10
  start-page: 1665
  year: 1991
  ident: 10.1136/ard.2008.095299_bib16
  article-title: A general parametric approach to the meta-analysis of randomized clinical trials.
  publication-title: Stat Med
  doi: 10.1002/sim.4780101105
– volume: 43
  start-page: 1129
  year: 2004
  ident: 10.1136/ard.2008.095299_bib1
  article-title: Prevalence of systemic sclerosis in a French multi-ethnic county.
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keh253
– volume: 318
  start-page: 1728
  year: 1988
  ident: 10.1136/ard.2008.095299_bib17
  article-title: An assessment of clinically useful measures of the consequences of treatment.
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198806303182605
SSID ssj0000818
ssib004908818
ssib058687963
ssib000829615
ssib002399310
ssib023363018
ssib008873822
ssib058492239
Score 2.1188018
Snippet Objective:To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research...
Objective: To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research...
To describe methods and procedures used for the development of the European League Against Rheumatism (EULAR)/EULAR Scleroderma Trial and Research group...
SourceID proquest
pubmed
pascalfrancis
crossref
nii
istex
bmj
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 629
SubjectTerms Biological and medical sciences
Consensus Development Conferences as Topic
Diseases of the osteoarticular system
Evidence-Based Medicine
Evidence-Based Medicine - methods
Evidence-Based Medicine; Humans; Randomized Controlled Trials as Topic; Research Design; Scleroderma, Systemic; Treatment Outcome; Consensus Development Conferences as Topic; Review Literature as Topic
Humans
Lung diseases
Medical sciences
Miscellaneous. Osteoarticular involvement in other diseases
Pulmonary hypertension
Questionnaires
Randomized Controlled Trials as Topic
Research Design
Review Literature as Topic
Rheumatism
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
Scleroderma
Scleroderma, Systemic
Scleroderma, Systemic - drug therapy
Stem cell transplantation
Steroids
Treatment Outcome
Title European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research
URI http://ard.bmj.com/content/68/5/629.full
https://api.istex.fr/ark:/67375/NVC-6MSDHVVQ-T/fulltext.pdf
https://cir.nii.ac.jp/crid/1871428067716692992
https://www.ncbi.nlm.nih.gov/pubmed/18957486
https://www.proquest.com/docview/1777857795
https://www.proquest.com/docview/67129701
Volume 68
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELfWVUK8IL4X2IolEBoPYc2HYwcJoTI6VWitoF_qW-TEzhZo09G0En8pfw93iZNqD4OXvNi-JPbl_Lvc-X6EvOmGqc_B-NquBl_VZ0LZEjZmW3k6iV1Qa-XiAefhKBjM_K8Ltjggo_osDKZV1jaxNNRqneA_8jOHcy4Y5yH7dPPLRtYojK7WFBrSUCuoj2WJsRZpg0kWoPftz_3Rt_HeNgtH1Bx6fhhwU-zH8YIzWBCTWhkyF0vBtuLVj1u7VRsn_jc05FmGOZSygGlMK_6LuwFquVFdPCQPDMKkvUolHpEDnT8m94Ymhv6E_Kl_wNNLLa92mvauZAYgkY6v9Q7xa7Gip_3ZZW_8jk5AwgbZ0laSTlFVqcwVrbP1aHkkBDtPptgbnevVShuapoICHqaAL2mTzE7XKa1KR2cJLUrZRVZ8oBWNdYHNeq-V5b02utgtt8V-JFaYpcumGDQ11Yqun5LZRX96PrANu4MdMz_Y2ggssDqgDBVgQK6TlIdhHDMvSJhIfQ9wFaALzbtCc8YSJwbHSyece4pJFjLpPSOH-TrXR4RyXyRcJAr6xn4qEoB8TCF2dGMZCqUs8hrWMrqp6ndEpd_jBRGsuGHhLFfcIu_rtY4SUyAdeTqWdw84bQb8V_bbUnmafnLzE1PqOItG8_MoGE6-DObz79HUIiegXXB_vDrgzfoY-ubg1QbwVqFrkc4tvWsEuo7noT9tkeNaESNjjopo__FY5FXTDIYEo0My1-tdAU8D0I93QcDzSn337yRCBlMcvPi36JfkfhVqw2zQY3K43ez0CSC2bdwhLb7gHfMx_gVJajzv
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF61iQRcEG8MfazEQ-VgGj_WayNVKLSpUppEkJd6M2t73QYSp2QTAX-On8HvYcZeO-qhcOoll12PY8_szDfe2fkIedkIUpeD8zVtCbmqy_zEFBCYzcSRcWSDWSc2HnDu9rz2yP14xs42yO_yLAyWVZY-MXfUyTzGb-T7FufcZ5wH7P3ldxNZo3B3taTQEJpaITnIW4zpgx2n8tcPSOHUwckR6PuVbR-3hodtU7MMmBFzvaWJAQ671IkgASzCZZzyIIgi5ngx81PXgfgOUU7yhi85Y7EVQQIgY86dhAkWMOGA3E1Sd_GEa43UP7R6n_rrWOBbfsnZ5wYe182FLMfbBwPQpZwBs7H17GY0-3olOtZR0T9hIJtMsGZTKFBbWvBtXA-I88B4fI_c1YiWNgsTvE82ZPaA3OrqPfuH5E_5wZ92pDhfSdo8FxMApbR_IVeIl9WM7rVGnWb_DR2AhAWys80EHeLSoCJLaFkdSPMjKDh5MMTZmMzPZlLTQikK-JsCnqVV8Tydp7RoVT2Jqcplq4l6RwvabIXDcr0K8nstpFpNl2p9JXa0pdOq-TTV3ZEuHpHRjej5Mall80w-JZS7fsz9OIG5kZv6MUBMliBWtSMR-ElikBegy_Cy6BcS5nmW44Wgcc36mWvcIG9LXYexbsiOvCDT6y_Yqy74r-zXufFU88TiG5bwcRb2xoeh1x0ctcfjz-HQINtgXXB__LUge3Zxq51DFu3BUwW2QXau2F0l0LYcB_N3g2yVhhhq96fC9WI1yG41DI4Ld6NEJucrBf8GoCZvgIAnhfmun8kPGLxi79m_Re-S2-1htxN2Tnqnz8mdYpsPK1G3SG25WMltQIvLaEcvSUq-3LQX-AtyInad
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF61iVRxQbwx9LESD5WDm_ixXhupQqFJlNIkKnmpN7O2120gcUqcCPiL_AB-DzP22lEPhVMvuex6HHtmZ77xzs5HyOu6F9scnK9uSshVbeZGuoDArEeWDAMTzDoy8YBzr-90xvanC3axRX4XZ2GwrLLwiZmjjhYhfiOvGZxzl3HusVqsyiLOm-0P1991ZJDCndaCTkMomoXoOGs3pg55nMlfPyCdS49Pm6D7N6bZbo1OOrpiHNADZjsrHYMddqwTXgS4hMsw5p4XBMxyQubGtgWxHiKe5HVXcsZCI4BkQIacWxETzGPCArnbpMohStoVUv3Y6p8PNnHBNdyCv8_2HK4aDRmWUwNjUGWdHjOxDe12MP96I1JWUek_YSCZTrF-U6Sgwjjn3rgdHGdBsv2A3FfoljZyc3xItmTyiOz01P79Y_Kn-PhPu1JcriVtXIopAFQ6uJJrxM7pnB62xt3G4B0dgoQlMrXNBR3hMqEiiWhRKUiz4yg4eTjC2ZjYz-dSUUSlFLA4BWxLy0J6uohp3rZ6GtI0k51O0_c0p9BOcVhuVkR2r6VM17NVurkSu9vSWdmImqpOSVdPyPhO9PyUVJJFIp8Tym035G4YwdzAjt0Q4CaLELeagfDcKNLIK9Clf533DvGznMtyfNC4YgDNNK6Ro0LXfqiasyNHyOz2Cw7LC_4r-21mPOU8sfyG5Xyc-f3Jie_0hs3OZPLZH2lkD6wL7o-_BmTSNm67c8ioHXgqz9TI_g27KwWahmVhLq-R3cIQfeUKU3-zcDVyUA6DE8OdKZHIxTqFfwOwk9dBwLPcfDfP5HoMXrHz4t-iD8gOeAO_e9o_e0nu5Tt-WJS6Syqr5VruAXBcBftqRVLy5a6dwF8yDnrJ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=European+League+Against+Rheumatism+%28EULAR%29+Scleroderma+Trial+and+Research+group+%28EUSTAR%29+recommendations+for+the+treatment+of+systemic+sclerosis%3A+methods+of+elaboration+and+results+of+systematic+literature+research&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Avouac%2C+J&rft.au=Kowal-Bielecka%2C+O&rft.au=Landewe%2C+R&rft.au=Chwiesko%2C+S&rft.date=2009-05-01&rft.pub=BMJ+Publishing+Group+Ltd+and+European+League+Against+Rheumatism&rft.issn=0003-4967&rft.eissn=1468-2060&rft.volume=68&rft.issue=5&rft.spage=629&rft_id=info:doi/10.1136%2Fard.2008.095299&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_NVC_6MSDHVVQ_T
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon